Purpose. The treatment of cancer-induced anemia with erythropoietin-stimulating agents (ESAs) is reviewed. Summary. Before the introduction of ESAs, the only treatment option for cancer-related ...
Figure 1: The pathophysiology of the cardiorenal syndrome and its effect on erythropoietin. Erythropoietic agents were introduced in about 1990 for the treatment of anemia associated with CKD.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback